The largest opportunities for organ regeneration lie in diseases/disorders of the bone marrow, kidneys, liver, pancreas, and small intestine. Market segments covered by this report include bioartificial kidneys and livers/liver regeneration products, bone marrow regeneration products, pancreas regeneration products, and small intestine replacement products. Various tissue engineering technologies including genes, scaffolds, stem cells, and xenotransplants are being researched for applications in organ regeneration.
This new report also provides a clinical overview of selected diseases/disorders that are amenable to treatment with tissue-engineered and cell transplantation products and includes the most up-to-date incidence and prevalence figures.
This report is the fifth in a series of six Medtech Insight reports covering U.S. tissue engineering and cell transplantation markets. The final report in this series will provide an analysis of the U.S. market for tissue-engineered skin replacement and skin substitute products.
EXECUTIVE SUMMARY i. Clinical Applications for Organ Regeneration a. Bone Marrow Disease b. Diabetes c. Intestinal Disorders d. Kidney Disease e. Liver Disease ii. Tissue Engineering Technologies a. Biomaterials b. Cell Culture Technology c. Stem Cell Technology d. Immunoisolation Technology iii. Technologies Under Development for Organ Regeneration a. Bone Marrow Regeneration Technologies b. Intestine Regeneration Technologies c. Kidney Regeneration Technologies d. Liver Regeneration Technologies e. Pancreas Regeneration Technologies f. Bioartificial Organ Technologies iv. Market Analysis v. Methodology Exhibit ES-1: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 1. CLINICAL OVERVIEW OF TISSUE ENGINEERING APPLICATIONS FOR ORGAN REGENERATION 1.1 Disease Incidence 1.1.1 Bone Marrow Disease 220.127.116.11 Aplastic Anemia 18.104.22.168 Leukemia and Lymphoma 1.1.2 Diabetes 1.1.3 Intestinal Disorders 22.214.171.124 Intestinal Pseudo-Obstruction 126.96.36.199 Microvillus Inclusion Disease 188.8.131.52 Short Bowel Syndrome 1.1.4 Kidney Disease 1.1.5 Liver Disease 1.2 Existing Therapies 1.2.1 Ex Vivo Systems 184.108.40.206 Kidney Dialysis Systems 1.2.2 Organ Transplantation 220.127.116.11 Bone Marrow Transplantation 18.104.22.168 Kidney Transplantation 22.214.171.124 Liver Transplantation 126.96.36.199.1 Split Cadaveric Livers 188.8.131.52.2 Liver Segments from Living Donors 184.108.40.206 Pancreas Transplantation 220.127.116.11 Intestinal Transplantation Exhibit 1-1: Incidence and Prevalence of Major Organ Diseases/Disorders Exhibit 1-2: Organ Transplantation, by Type, Procedure Volumes, and Waiting List Exhibit 1-3: Average Estimated First-Year Billed Charges, Per Transplant 2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES 2.1 Biomaterials 2.1.1 Synthetic Biomaterials 2.1.2 Biologically Derived Biomaterials 18.104.22.168 Collagen 22.214.171.124 Xenogeneic Tissue 2.1.3 Hybrid Biomaterials 2.1.4 Genetically Engineered Biomaterials 126.96.36.199 Deoxyribonucleic Acid Transfection Vectors 188.8.131.52 Genetically Manipulated Cells 184.108.40.206 Three-Dimensional Polymer Technology 220.127.116.11 Transgenics 18.104.22.168 Fibroblasts 22.214.171.124 Immortalized Neural Stem Cells 126.96.36.199 Gene-Activated Matrices 2.1.5 Scaffolds 2.1.6 Vascular Grafts 2.2 Cell Culture Technology 2.2.1 Bioreactors 188.8.131.52 Flatbed Perfusion Systems 184.108.40.206 Hollow Fiber Bioreactor Systems 220.127.116.11 Cell Suspension Systems 18.104.22.168 Disposable Bioreactors 2.3 Stem Cell Technology 2.3.1 Cell Extraction and Expansion 2.3.2 Bioreactors 2.4 Immunoisolation Technology 2.4.1 Chimeric Immunity 2.4.2 Cell Encapsulation Technology Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies 3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: U.S. MARKETS FOR ORGAN REGENERATION PRODUCTS 3.1 Emerging Technologies and Products 3.1.1 Genes 3.1.2 Scaffolds 3.1.3 Stem Cells 3.1.4 Xenotransplants 3.1.5 Bone Marrow 22.214.171.124 Gamida Cell 126.96.36.199 Osiris Therapeutics 188.8.131.52 SituGen 184.108.40.206 University of Texas M.D. Anderson Cancer Center and the ViaCord Research Institute/ViaCord/PerkinElmer 3.1.6 Intestine 3.1.7 Kidney 220.127.116.11 Tengion 3.1.8 Liver 18.104.22.168 Cytonet 22.214.171.124 StemCells 126.96.36.199 Vesta Therapeutics 3.1.9 Pancreas 188.8.131.52 BioTime 184.108.40.206 Cerco Medical 220.127.116.11 Geron 18.104.22.168 Juvenile Diabetes Research Foundation 22.214.171.124 Osiris Therapeutics 126.96.36.199 ViaCyte 188.8.131.52 StemCells 184.108.40.206 TheraCyte 220.127.116.11 Transition Therapeutics 18.104.22.168 ViaCord/PerkinElmer 22.214.171.124 Vitro Biopharma/Vitro Diagnostics 3.2 Artificial Organ Technologies 3.2.1 Bioartificial Kidney 3.2.2 Bioartificial Liver 126.96.36.199 Excorp Medical 188.8.131.52 Gambro 184.108.40.206 HepaLife Technologies 220.127.116.11 Hep-Art Medical Devices 18.104.22.168 Hybrid Organ 22.214.171.124 Vital Therapies 126.96.36.199 Xenogenics/MultiCell Technologies 3.2.3 Artificial Pancreas 188.8.131.52 Juvenile Diabetes Research Foundation 184.108.40.206 Medtronic 3.3 Market Analysis 3.3.1 Market Drivers 3.3.2 Market Limiters 3.4 Competitors Exhibit 3-1: 2010, Selected Emerging Treatment Products for Liver Failure Exhibit 3-2: 2010, Selected Emerging Treatment Products for Pancreatic Failure Exhibit 3-3: 2010, Selected Bioartificial and Artificial Organ Products Exhibit 3-4: Medtronic's STAR 3 Study Results Exhibit 3-5: Organ Regeneration Products, Potential Market Forecast, 2009 and 2019 Exhibit 3-6: Organ Regeneration Technologies, by Indication, 2009 and 2019 4. COMPANY PROFILES 4.1 BioTime, Inc. 4.2 Cerco Medical LLC 4.3 Cytonet GmbH & Co. KG 4.4 Geron Corporation 4.5 Osiris Therapeutics, Inc. 4.6 PerkinElmer, Inc. 4.7 StemCells, Inc. 4.8 Tengion, Inc. 4.9 Vesta Therapeutics, Inc. 4.10 ViaCyte, Inc. APPENDIX: COMPANY LISTING